Skip to content
drillr.ai
Sign up

688331.SH

荣昌生物

SSE · Healthcare · Biotechnology · CN

CNY 116.42
−7.24%
Ask drillr

  • Aug 31, 2026, 23:17 UTC

    China's 2026 National Essential Medicines List took effect on September 1, adding 116 new drugs including four domestic Class 1 innovative drugs and Novo Nordisk's semaglutide.

    Source:

  • Aug 24, 2026, 09:34 UTC

    RemeGen Co., Ltd. announced its 2026 interim results, reporting a net profit of 4.662 billion yuan, turning from a loss in the prior year.

    Source:

  • Aug 21, 2026, 11:48 UTC

    AbbVie presented clinical data from its lung cancer research programs at the 2026 World Conference on Lung Cancer, including Phase 1b results for ABBV-1480 and a Phase 1b/2 study for telisotuzumab adizutecan.

    Source:

  • Aug 18, 2026, 19:54 UTC

    RemeGen forecast first-half 2026 revenue of 5.85 billion yuan.

    Source:

  • Aug 5, 2026, 13:29 UTC

    RemeGen issued a profit alert, expecting a net profit of about 4.7 billion RMB for the six months ended June, turning from a loss of 450 million RMB in the same period last year; revenue was about 5.85 billion RMB, up 433% year-on-year.

    Source:

  • Jul 20, 2026, 02:00 UTC

    Multiple A-share listed companies including Victory Giant Technology, RemeGen, and Huaan Securities issued share buyback announcements.

    Source:

  • Jul 19, 2026, 08:43 UTC

    Rongchang Biologics announced a share buyback plan of 25-50 million yuan at a price not exceeding 149 yuan per share.

    Source:

  • Jun 8, 2026, 12:31 UTC

    China's NMPA approved telitacicept for the treatment of Sjögren's disease in adult patients, based on Phase 3 results from RemeGen.

    Source: